Scarica l'app Stockscreener
113.17
2.38%
2.63
Pre-mercato:
114.40
1.23
+1.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$110.54
Aprire:
$113.2
Volume 24 ore:
1.50M
Relative Volume:
1.02
Capitalizzazione di mercato:
$12.63B
Reddito:
$2.90B
Utile/perdita netta:
$239.11M
Rapporto P/E:
53.64
EPS:
2.1097
Flusso di cassa netto:
$492.62M
1 W Prestazione:
+1.32%
1M Prestazione:
+13.28%
6M Prestazione:
-3.05%
1 anno Prestazione:
+13.80%
Intervallo 1D:
$110.91
$116.00
Intervallo di 1 settimana:
$102.36
$116.00
Portata 52W:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Nome
Revvity Inc
Settore
Industria
Telefono
781-663-6900
Indirizzo
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
113.17 | 12.63B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-12-09 | Iniziato | Goldman | Neutral |
| 2025-10-16 | Iniziato | Guggenheim | Neutral |
| 2025-05-01 | Aggiornamento | UBS | Neutral → Buy |
| 2025-01-10 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-08 | Iniziato | Leerink Partners | Outperform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-23 | Ripresa | Goldman | Buy |
Mostra tutto
Revvity Inc Borsa (RVTY) Ultime notizie
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs - FinancialContent
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance UK
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity, Inc. (RVTY) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Insider Sell Alert: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning - simplywall.st
Revvity to Launch Signals for Startups for Emerging Biotech Companies - The Globe and Mail
Revvity Inc. Stock Slides 3.4%, Underperforms Peers - webull.com
Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation - Ad-hoc-news.de
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity Inc (RVTY) Stock Down 3.4% -- Now Undervalued? GF Score: 72/100 - GuruFocus
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - 01net
RVTY (RVTY) investor files notice to sell 85 common shares - Stock Titan
Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing - Stock Titan
Revvity launches “Signals for Startups” to give emerging biotechs an enterprise-grade digital edge - Indian Chemical News
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure - Lelezard
Revvity stock trades steadily as recent earnings highlight margin focus - Ad-hoc-news.de
PKI5144059 Bond Coupon Profile — Rate & Payments - TradingView
Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan - Stock Titan
PKI5144059 Bond Profile — Key Metrics - TradingView
XS1405780617 Bond Coupon Profile — Rate & Payments - TradingView
XS1405780617 Bond Risk Profile - TradingView
PKI5255604 Bond Risk Profile - TradingView
XS1405780617 Bond Profile — Key Metrics - TradingView
Revvity stock trades steady as genomics and diagnostics revenue underpins valuation - Ad-hoc-news.de
Revvity, Inc. (PKN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (PKN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
PKI5255604 Bond Profile — Key Metrics - TradingView
PKI5255604 Bond Coupon Profile — Rate & Payments - TradingView
Revvity stock trades steadily as recent earnings highlight growth and margin pressure - Ad-hoc-news.de
Revvity Inc. stock outperforms competitors on strong trading day - MSN
Revvity (RVTY) Q4 2025 earnings summary - Quartr
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating - marketscreener.com
REVVITY INC : TD COWEN RAISES TARGET PRICE TO $130 FROM $120 - Moomoo
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $130 - Moomoo
Revvity (RVTY) Investor Day 2024 Summary - Quartr
Revvity (RVTY) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Revvity (RVTY) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
PKI4882935 Bond Risk Profile - TradingView
A184AM Bond Risk Profile - TradingView
A184AM Bond Coupon Profile — Rate & Payments - TradingView
S&P Global upgrades Revvity outlook on leverage improvement By Investing.com - Investing.com Nigeria
A184AM Bond Profile — Key Metrics - TradingView
PKI5255603 Bond Profile — Key Metrics - TradingView
S&P Global upgrades Revvity outlook on leverage improvement - Investing.com
Revvity: Overvalued On Sentiment (NYSE:RVTY) - Seeking Alpha
The path to AI federated learning for drug discovery - Scientific Computing World
Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating - marketscreener.com
Revvity Inc Azioni (RVTY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
8.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):